α-Fluormethylornithin | 111766-96-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-Fluormethylornithin
• 英文别名: 2,5-diamino-2-(fluoromethyl)pentanoic acid；2-Fluoromethyl-2,5-diaminopentanoic acid；2-fluoromethyl-2,5-diaminovaleric acid；α-monofluoromethylornithine；2-Fluoromethylornithine
• CAS: 111766-96-2
• 化学式: C₆H₁₃FN₂O₂
• 分子量: 164.18
• InChiKey: PYSFCFGTQFSVRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  α-Fluormethylornithin 生成 3-Amino-3-fluormethyl-2-piperidon
  参考文献：
  名称：

  BEY, PHILIPPE;JUNG, MICHEL

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Amino-3-fluormethyl-2-piperidon 生成 α-Fluormethylornithin
  参考文献：
  名称：

  BEY, PHILIPPE;JUNG, MICHEL

  摘要：

  DOI：

文献信息

• S-Adenosylmethionine decarboxylase inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0351475A1

  公开（公告）日：1990-01-24

  This invention relates to novel chemical compounds useful as S-adenosylmethionine decarboxylase inhibitors, of the formula H₂N-Q--Al wherein Al represents 5'-deoxyadenosyl.      represents adenosinyl, R represents H, methyl or ethyl and Q represents moieties of formulae Ia to If depicted as follows: wherein R₁ is H or F, n is 1 or 2, V₁ is H or CH₃, V₂ is H or COOH, and each of W, X, Y, and Z are H, F, Cl or Br. To the processes useful for their preperation and to their use in the treatment of a variety of condition and disease states associated with a rapid proliferation of cell growth.

  这项发明涉及一种新型化合物，可用作S-腺苷甲硫氨酸脱羧酶抑制剂，其化学式为H₂N-Q--Al，其中Al代表5'-去氧腺苷基。     代表腺苷基，R代表H、甲基或乙基，Q代表如下所示的化学式Ia至If的基团：其中R₁为H或F，n为1或2，V₁为H或CH₃，V₂为H或COOH，而W、X、Y和Z中的每一个均为H、F、Cl或Br。还涉及用于其制备的方法以及它们在治疗与细胞增殖快速增加相关的各种疾病和病症中的应用。
• Polyamine-metal chelator conjugates
  申请人：Bergeron J. Raymond

  公开号：US20060211773A1

  公开（公告）日：2006-09-21

  Many metal collators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyimide-metal collator conjugates of the invention are compounds comprising a first moiety which is a metal collator and a second moiety which is a polyimide, where the polyimide moiety includes three or more nitrogen atoms which are capable of being positively charged at physiological pH. A sperms-L1 conjugate has been shown to accumulate in L1210 cells several hundred fold more than the unconjugated L1 chelator.

  许多金属配体具有极性或带电的功能基团，这使它们难以穿过细胞膜。本发明的聚酰亚胺-金属配体共轭物是由第一部分为金属配体，第二部分为聚酰亚胺的化合物组成，其中聚酰亚胺部分包含三个或更多的氮原子，在生理pH下能够呈正电荷。已经证明，精子-L1共轭物在L1210细胞中的积累量比未共轭的L1螯合剂高出数百倍。
• Polyamine-Metal Chelator Conjugates
  申请人：Bergeron Raymond

  公开号：US20080096974A2

  公开（公告）日：2008-04-24

  Many metal chelators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyamine-metal chelator conjugates of the invention are compounds comprising a first moiety which is a metal chelator and a second moiety which is a polyamine, where the polyamine moiety includes three or more nitrogen atoms which are capable of being positively charged at physiological pH. A spermine-L1 conjugate has been shown to accumulate in L1210 cells several hundred fold more than the unconjugated L1 chelator.

  许多金属螯合剂具有极性或带电的功能基团，这使得它们难以跨越细胞膜。本发明的多胺-金属螯合剂共轭物是化合物，包括第一部分是金属螯合剂，第二部分是多胺，其中多胺部分包括三个或更多的氮原子，在生理pH下能够呈正电荷。已经证明精胺-L1共轭物在L1210细胞中的积累比未共轭的L1螯合剂高出数百倍。
• Preparation of aminoacetonitrile derivatives
  申请人：MERRELL TORAUDE ET COMPAGNIE

  公开号：EP0046710A1

  公开（公告）日：1982-03-03

  2-Fluorinated methyl aminoacetonitriles are prepared by treating a corresponding fluorinated methyl ketimine magnesium halide with hydrogen cyanide or with an alkali metal cyanide or ammonium cyanide and a proton source.

  用氰化氢或碱金属氰化物或氰化铵和质子源处理相应的氟化甲基酮亚胺卤化镁，可制备 2-氟化甲基氨基乙腈。
• Polyamine for use as a medicine in the treatment of neoplasms
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0162413A2

  公开（公告）日：1985-11-27

  This invention relates to the use of certain polyamines in the treatment of neoplasms or in conjunctive therapy with ornithine decarboxylase inhibitors and/or S-adeno-sylme- thionine decarboxylase inhibitors or in conjunction with other known cytotoxic agents, or with interferon.

  本发明涉及某些多胺在治疗肿瘤或与鸟氨酸脱羧酶抑制剂和/或 S-腺苷-硫氨酸脱羧酶抑制剂或与其他已知的细胞毒剂或干扰素联合治疗中的应用。